Open AccessEradication therapy of helicobacteriosis with probiotics, problems, and prospects
Author(s) -
Е. И. Ермоленко,
А С Молостова,
Nikita Gladyshev
Publication year - 2021
Publication title -
èksperimentalʹnaâ i kliničeskaâ gastroènterologiâ
Language(s) - English
Resource type - Journals
ISSN - 1682-8658
DOI - 10.31146/1682-8658-ecg-193-9-60-72
Subject(s) - medicine , probiotic , helicobacter pylori , antibiotics , gastrointestinal tract , pathogen , antibiotic therapy , intensive care medicine , microbiology and biotechnology , immunology , bacteria , biology , genetics
Currently, there is an urgent question of optimizing the treatment of stomach diseases associated with Helicobacter pylori, due to the increasing resistance of the pathogen to antibiotics and the presence of side effects of standard therapy. To optimize it, it is proposed to use probiotics as an additional or monotherapy. The review presents the results of studies of anti-helicobacter activity by in vitro and in vivo systems, as well as an assessment of the clinical effectiveness of various probiotic strains of microorganisms in eradication therapy. Several mechanisms of action of probiotics in the treatment of HP-related diseases are discussed. The problems and prospects of using personalized therapy of helicobacteriosis with probiotics and autoprobiotics, based on strains obtained from the gastrointestinal tract, are indicated.